Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results come from ClinicalTrials.gov. When the live registry is unavailable, a clearly labeled stored copy may be shown.

Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Oct 7, 2026, 10:41 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–7 of 7 matching trials from the live ClinicalTrials.gov search.
Filters: Sponsor: Lux Biosciences, Inc. Clear all
Completed Phase 3 Interventional

Efficacy and Safety of Voclosporin to Treat Active Noninfectious Uveitis

NCT01243983
View directory record Official record
Conditions
Noninfectious Uveitis
Interventions
LX211
Drug
Lead sponsor
Lux Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
155 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2012
U.S. locations
28
States / cities
Peoria, Arizona • Phoenix, Arizona • Little Rock, Arkansas + 24 more
Source: ClinicalTrials.gov public record
Updated Jan 10, 2013 · Synced Oct 7, 2026, 10:41 AM EDT
Completed Phase 3 Interventional

A Multi-center Study to Assess the Efficacy and Safety of LX211 in Active Non-infectious Anterior Uveitis

NCT00404885
View directory record Official record
Conditions
Uveitis, Anterior, Panuveitis
Interventions
Placebo, LX211
Drug
Lead sponsor
Lux Biosciences, Inc.
Industry
Eligibility
13 Years and older
Enrollment
108 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
14
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chicago, Illinois + 11 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Oct 7, 2026, 10:41 AM EDT
Completed Phase 1 Interventional Accepts healthy volunteers

A Dose-Escalation Study to Assess the Safety and Tolerability of LX214 Ophthalmic Solution in Healthy Volunteers, Followed by an Open-Label Evaluation of LX214 in Patients With Keratoconjunctivitis Sicca (KCS)

NCT00851734
View directory record Official record
Conditions
Keratoconjunctivitis Sicca
Interventions
voclosporin ophthalmic solution
Drug
Lead sponsor
Lux Biosciences, Inc.
Industry
Eligibility
18 Years to 55 Years
Enrollment
35 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Conshohocken, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Oct 7, 2026, 10:41 AM EDT
Terminated Phase 3 Interventional

Study to Assess LX201 for Prevention of Corneal Allograft Rejection or Graft Failure in Subjects Who Have Experienced One or More Rejection Episodes Following Penetrating Keratoplasty

NCT00447642
View directory record Official record
Conditions
Corneal Transplantation, Corneal Graft Rejection
Interventions
LX201, Placebo
Drug · Other
Lead sponsor
Lux Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
122 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
24
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 7, 2026, 10:41 AM EDT
Terminated Phase 3 Interventional

Study to Assess the Efficacy and Safety of LX201 for Prevention of Corneal Allograft Rejection Episodes and Graft Failure in Subjects at Increased Immunological Risk

NCT00447187
View directory record Official record
Conditions
Corneal Diseases, Cornea Transplant
Interventions
LX201, Placebo
Drug · Other
Lead sponsor
Lux Biosciences, Inc.
Industry
Eligibility
18 Years and older
Enrollment
368 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2010
U.S. locations
24
States / cities
Phoenix, Arizona • Loma Linda, California • Los Angeles, California + 19 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 7, 2026, 10:41 AM EDT
Completed Phase 3 Interventional

A Study of LX211 in Clinically Quiescent Non-infectious Intermediate, Anterior and Intermediate, Posterior or Pan-Uveitis

NCT00404742
View directory record Official record
Conditions
Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
Interventions
Placebo, LX211
Drug
Lead sponsor
Lux Biosciences, Inc.
Industry
Eligibility
13 Years and older
Enrollment
232 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chicago, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Jun 22, 2012 · Synced Oct 7, 2026, 10:41 AM EDT
Completed Phase 3 Interventional

A Study of LX211 in Active Sight Threatening, Non-infectious Intermediate-, Anterior and Intermediate-, Posterior-, or Pan-Uveitis

NCT00404612
View directory record Official record
Conditions
Uveitis, Posterior, Uveitis, Intermediate, Panuveitis
Interventions
Placebo, LX211
Drug
Lead sponsor
Lux Biosciences, Inc.
Industry
Eligibility
13 Years and older
Enrollment
218 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2009
U.S. locations
19
States / cities
Birmingham, Alabama • Phoenix, Arizona • Chicago, Illinois + 16 more
Source: ClinicalTrials.gov public record
Updated Oct 11, 2012 · Synced Oct 7, 2026, 10:41 AM EDT